Free Trial

Inotiv Q3 2023 Earnings Report

Inotiv logo
$4.74 -0.12 (-2.47%)
(As of 04:45 PM ET)

Inotiv EPS Results

Actual EPS
$0.07
Consensus EPS
$0.26
Beat/Miss
Missed by -$0.19
One Year Ago EPS
N/A

Inotiv Revenue Results

Actual Revenue
$157.47 million
Expected Revenue
$147.77 million
Beat/Miss
Beat by +$9.70 million
YoY Revenue Growth
N/A

Inotiv Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

Inotiv Earnings Headlines

Investors Buy Large Volume of Call Options on Inotiv (NASDAQ:NOTV)
Inotiv’s Strategic Moves and Financial Outlook Support Buy Rating
TSLA *BANG* incoming (bullet in the chamber rn)
I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’s promise, and a secret Elon project set to revolutionize a $23 Trillion market…
Inotiv Shares Drop on $25.5 Mln Public Offering
See More Inotiv Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inotiv? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inotiv and other key companies, straight to your email.

About Inotiv

Inotiv (NASDAQ:NOTV) provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

View Inotiv Profile

More Earnings Resources from MarketBeat